Literature DB >> 12427803

Non-alcoholic steatohepatitis (NASH): why biopsy?

A McNair.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 12427803      PMCID： PMC1773490          DOI： 10.1136/gut.51.6.898

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  5 in total

1.  How are abnormal results for liver function tests dealt with in primary care? Audit of yield and impact.

Authors:  P Sherwood; I Lyburn; S Brown; S Ryder
Journal:  BMJ       Date:  2001-02-03

Review 2.  Liver biopsy: review of methodology and complications.

Authors:  A I Tobkes; H J Nord
Journal:  Dig Dis       Date:  1995 Sep-Oct       Impact factor: 2.404

3.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.

Authors:  C A Matteoni; Z M Younossi; T Gramlich; N Boparai; Y C Liu; A J McCullough
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

4.  Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes?

Authors:  M M Van Ness; A M Diehl
Journal:  Ann Intern Med       Date:  1989-09-15       Impact factor: 25.391

5.  The natural history of nonalcoholic fatty liver: a follow-up study.

Authors:  M R Teli; O F James; A D Burt; M K Bennett; C P Day
Journal:  Hepatology       Date:  1995-12       Impact factor: 17.425
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.